Silo Pharma Enters into Sponsored Research Agreement with Columbia University to Develop Psychedelic Therapeutics for Alzheimer’s Disease Englewood Cliffs, NJ, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...

Adult Stem Cells Might Help Some Patients with Alzheimer Disease, Reports Journal of American Physicians and Surgeons TUCSON, Ariz., March 25, 2019 (GLOBE NEWSWIRE) -- Promising results in animal models of neurodegenerative diseases suggest that a patient’s own stem cells, derived from his fat tissue or bone...